Press Releases & Statements

Investor Relations

Novavax to Participate in Upcoming September Conferences
Sep 9, 2021

GAITHERSBURG, Md., Sept. 9, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

H.C. Wainwright 23rd Annual Global Investment Conference (Virtual)

Fireside Chat


Date:

Monday, September 13, 2021


Time:

Available on-demand starting at 7:00 a.m. Eastern Time (ET)


Moderator:

Vernon Bernardino


Novavax participants:

Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer





Panel


Date:

Wednesday, September 15, 2021

Time:

Available on-demand starting at 12:00 p.m. Eastern Time (ET)

Panel Title:

Best Practices – Planning for the Next Pandemic

Moderator:

Scott Gottlieb, M.D., Physician; Former Commissioner FDA

Panelist:

John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer





Morgan Stanley 19th Annual Global Healthcare Conference (Virtual)

Fireside Chat


Date:

Friday, September 10, 2021


Time:

2:00 – 2:30 p.m. Eastern Time (ET)


Moderator:

Jeffrey Hung


Novavax participants:

Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer






Recordings
All replays of the recorded fireside sessions will be available through the events page of the Company's website at ir.novavax.com for 90 days from the date of the conference.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:     
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com

Media
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
media@novavax.com

 

Novavax Logo (PRNewsfoto/Novavax)

 

SOURCE Novavax, Inc.